

GALIL MEDICAL ANNOUNCES COLUMBIA UNIVERSITY MEDICAL CENTER ENROLLS FIRST PATIENT IN RENAL TRACE REGISTRY

Arden Hills, MN—October 8, 2010 —Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that Columbia University Medical Center enrolled their first TRACE Registry patient.

The TRACE (Tracking Renal Tumors After Cryoablation Evaluation) Registry will allow physicians and the company to follow and evaluate the use and effectiveness of cryotherapy treatment for patients with renal masses. Cryotherapy is a minimally invasive procedure using small cryoablation needles to target and freeze tumors and other suspicious masses.

"Renal cryoablation continues to be an increasingly important management strategy in the treatment of small renal cortical neoplasms. It is through well organized prospectively established multicenter studies that we will be able accurately demonstrate the safety and efficacy of kidney cryoablation procedures." said Dr. Jaime Landman, Associate Professor, Department of Urologic Surgery, Columbia University Medical Center. Dr. Landman is an expert in kidney cancer and is serving as scientific advisor for the multicenter study.

Standard treatment options for renal cell cancer include total and partial nephrectomies, open and laparoscopic procedures. Minimally invasive ablative therapies are increasingly accepted treatment options due to favorable clinical outcomes, reduced procedural pain, nephron sparing techniques, fewer complications and faster patient recovery.

Galil Medical initiated the TRACE Registry in May 2010 and expects to enroll an estimated 250 patients across approximately ten sites in the United States, including Columbia University Medical Center. Martin J. Emerson, President and CEO of Galil Medical commented, "Through the TRACE Registry we are fulfilling our commitment of developing robust clinical data."

About Galil Medical Galil Medical is a global leader in delivering innovative cryotherapy solutions. The company is addressing patient conditions across multiple physician specialties; treatment areas include conditions affecting bone, kidney, liver, lung and prostate, as well as targeted pain applications. Company offices are in Arden Hills, Minnesota; Yokneam, Israel; and London, United Kingdom. Shareholders include Thomas, Mc Nerney & Partners, The Vertical Group, and Investor Growth Capital.

Contact information:

Martin J. Emerson
President and CEO, Galil Medical
Tel: +1 651 287 5050
Email: marty.emerson@galilmedical.com

Bill Jacqmein
Chief Technology Officer
Tel: +1 651 287 5090
Email: Bill.Jacqmein@galilmedical.com